Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

SELL
$103.46 - $126.29 $10.3 Million - $12.6 Million
-100,000 Reduced 40.0%
150,000 $16.1 Million
Q1 2022

May 10, 2022

BUY
$30.13 - $50.0 $7.53 Million - $12.5 Million
250,000 New
250,000 $9.44 Million

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Decheng Capital Management Iii (Cayman), LLC Portfolio

Follow Decheng Capital Management Iii (Cayman), LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Decheng Capital Management Iii (Cayman), LLC, based on Form 13F filings with the SEC.

News

Stay updated on Decheng Capital Management Iii (Cayman), LLC with notifications on news.